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Abstract: Gene therapy concept is based on introduction of the wild-type allele into a patient’s genome in order to 
reverse a specific mutation. It is designed to treat hereditary diseases as well as the other diseases occurring later in life. 
Gene therapy was first mentioned in the 1960s and 70s, whereupon a series of studies was carried out, and in 1990 the 
first successful gene therapy was conducted. Since then about 2 600 clinical trials based on this concept were 
completed or are in progress. The two biggest issues are introduction of an exogenous DNA to target tissue, and its 
controlled integration in the genome. Until recently, the exogenous DNA sequences were incorporated randomly in the 
patient’s genome. Even though most of these treatments gave positive results, there was always a possibility of 
insertional mutagenesis. Controlling the integration place has rapidly progressed with the development of gene editing 
tools: ZFN, TALEN and CRISPR/Cas9.  Although they have been used in only several clinical studies, gene editing 
tools are a small step away from clinical usage. In this review, we will give historical overview of gene therapy 
development and describe recent tools that can be used in precision medicine. 
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In a paper from 1947, the term “Gene therapy” was 
first mentioned by Clyde E. Keeler.
1
 At the time, 
treatment of genetic disorders using the methods of 
traditional medicine resulted only in alleviating the 
symptoms but without curing the cause of the disease. 
Keeler noted that causes of genetic diseases in 
offspring were determined by genetic material in germ 
line cells of parents. Because of mechanisms of 
inheritance in human (e.g. crossing over), replacement 
of defective gene with the functional one can result in 
correction of defective hereditary characteristics. He 
concluded that this principle could solve a number of 
"genetic problems". In 1952 two important discoveries 
contributed to gene therapy development: Lederberg 
and Zinder described recombination between two 
bacteria where genetical material from one bacterium 
to another was carried by bacteriophage (transduction), 
and Hershey and Chase conducted experiment which 
proved that DNA is a carrier molecule of hereditary 
characteristics.
2, 3
 In 1962 the first hereditary gene 
transfer was described by Elizabeth Hunter Szybalska 
and Wacław Szybalski. They used the total genomic 
DNA with a functional copy of the HPRT1 gene 
(hypoxanthine phosphoribosyltransferase), to transform 
HPRT1-deficient D98S bone marrow cell line. That 
was the first success of human cells transformation in 
vitro.
4
 Basically, they showed that newly acquired 
hereditary feature, “incorporated feature”, is transferred 
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Beginnings of gene therapy 
In 1961, while studying chicken cells infected by Rous 
sarcoma virus (RSV), Howard Temin discovered that 
mutation caused by virus is stabilized in host cells and 
transferred to next cell generation. Given that RSV is 
an RNA virus, this was evidence that information 
stored in RNA genome can be incorporated into DNA.
5
 
It was showed that viruses might serve as a tool for 
insertion of a new gene in any cell, which was an 
interesting topic discussed by Edward Tatum shortly 
after.
6
 He suggested that if process of gene transfer 
between two bacteria by virus can be applied to animal 
cells, introduction of a functional gene into animal host 
genome to replace a defective gene of interest can be 
achieved. For such approach it was required to design a 
non-pathogenic viral vector. Although there was no 
mention of “gene therapy”, this paper brought 
description of its basic principles. In order to 
successfully edit patient’s genome, it would be 
necessary to propagate patient's cells in culture, 
transfect them with functional gene and re-introduce 
cells with wild-type gene back to the relevant tissue of 
the patient. Key point that later allowed conduction of 
such approach was usage of restriction enzymes, 
discovery for which Nobel prize was awarded to Arber, 
Nathans, and Smith in 1978.
7
 
The first attempt to treat a disease by introducing a 
foreign gene into the human genome was made in 
1970. Patients were two children with rare hereditary 
disease, hyperargininemia, caused by deficiency of 
arginase. In this disorder, because of accumulation of 
arginine in blood and liquor mental retardation occurs. 
Selected method of treatment was based on the fact that 
a rabbit infected by Shope papilloma virus (SPV) 
produces increased amounts of arginase. Moreover, in 
35% of laboratory workers exposed to that virus a 
decrease in arginine concentration can be seen.
8
 SPV 
was directly injected into the bloodstream of patients. 
There was no improvement in patients’ condition and it 
was debated if SPV has an arginase coding gene or if it 
just stimulates the arginase production in healthy 
individuals from the endogenous gene.
8
 Later was 
elucidated that the infection caused higher production 
of host arginase. Therefore, patients who lack 
functional arginase gene cannot be treated using this 
approach. Although this “gene therapy” attempt didn't 
have harmful effects on patients, it became evident that 
safer and more elaborate treatment methods should be 
designed prior to any further clinical application. 
In 1970 two independent groups discovered reverse 
transcriptase
9, 10
 - enzyme that transcribes RNA into 
complementary DNA coded by retroviruses to allow 
viral genome integration into the host genome can be 
used in vitro in order to transcribe any mRNA in the 
complementary DNA that can be than ligated into the 
virus vector and then after entering the cell, integrated 
into the host genome. This feature has become a key 
element in the technical implementation of gene 
therapy. 
In the same year, Victor McKusick Almond published 
comprehensive list of 92 genetic disorders in humans 
with exact enzymes whose deficiency caused a 
particular disease.
11
 Two years later, Theodore 
Friedmann and Richard Roblin discussed gene therapy 
as a desirable technique for treating hereditary 
diseases.
8
 Over 1 500 different genetic diseases were 
known at that time, with new ones being discovered 
frequently. The exact mechanisms underlying these 
diseases were still unknown, but associations of genetic 
defects with different diseases become more and more 
evident. Such diseases were commonly treated with 
adjusted diets e.g., diets with low-phenylalanine 
alleviate mental retardation in case of phenylketonuria. 
Second treatment option was usage of drugs which 
block or reduce the accumulation of potentially 
harmful metabolites, but at the time they were available 
for only a few genetic disorders such as cystinuria and 
Lesch-Nyhan syndrome. Third possible treatment was 
a direct introduction of a wild-type enzyme intended 
for enzymatic hereditary diseases. All these 
possibilities gave scarce results and gene therapy 
looked like a promising new option. 
In the paper from 1972, Friedmann and Roblin also 
discussed technical barriers, and proposed ethical 
standards that should be taken into consideration before 
applying the gene therapy in humans. They pointed out 
that because many human genes are expressed at a low 
level, and only in certain cell types, strategy for 
bringing exogenous DNA specifically to those cells 
should first be developed. Additionally, they 
emphasized a higher potential of cells whose genome 
was edited by in vitro treatment to develop malignant 
properties. Conclusion was that gene therapy should 
never put individual's life at risk, which is why it is 
necessary to first understand biochemical properties of 
the process intended to be affected, to consider 
differences in the diseases with a different genetic 
background, and to only apply a well-characterized and 
safe vector. For the same reasons, all new methods 
should be first tested on animals.
8
 Based on their 
recommendations, genome editing was planned to be 
used in clinic. 
 
 
Beginnings of clinical applications 
The first clinical implementation of gene therapy was 
done by Martin Cline. His approach was based on 
experiments showing effects of foreign genes for 
dihydrofolate reductase (DHFR) and thymidine kinase 
(TK) incorporated in mouse bone marrow cells.
12, 13
 In 
1980, without any approval from the institution, he 
treated two patients who were diagnosed with β-
thalassemia using this approach. β-thalassemia is 
caused by mutations in the human β-globin gene 
(HBB). Patients’ bone marrow cells were harvested and 
treated with the plasmid DNA which carried an 
integrated gene for β-globin. Modified cells were then 
returned to patients’ bone marrows.
14
 In the meantime, 
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his institution (The University of California, Los 
Angeles) declined the approval based on the fact that 
the same treatment has not previously been tested on 
animal models. Cline's work was declared unethical, 
and any similar treatment was forbidden.
15
 The 
treatment itself showed no results - introduced gene 
was not expressed. Nevertheless, Martin Cline is still 
regarded as the first scientist who used recombinant 
DNA in clinical treatment. 
At the beginning of 1989 National Institutes of Health 
gave official approval for the entry of a foreign gene 
into the human body to S. A. Rosenberg
16
 with an aim 
of improving melanoma treatment. In previous studies, 
it has been shown that treatment of metastatic 
melanoma with interleukin-2 simultaneously with in 
vitro expanded tumor infiltrating lymphocytes (TILs), 
in some patients reduced the progression of the 
disease.
17
 Therefore, it was necessary to define a 
connection between TILs activity and regression of 
malignant disease.  The method for this procedure was 
based on a marker that can help monitor distribution of 
TILs in patient’s tissues. TILs were isolated from the 
melanoma patients, modified by Moloney murine 
leukemia retrovirus with an incorporated marker gene, 
and injected back into the patients. It was shown that 
these cells can survive for months in the patient's body, 
and that retroviral vectors were a safe and simple 




In September 1990, Food and Drug Administration 
(FDA) approved first gene therapy that ended with 
success. Patients were two girls diagnosed with severe 
combined immunodeficiency (SCID). SCID is a rare 
autosomal recessive disease caused by B- and T-
lymphocytes developmental failure.
18
 It is caused by a 
mutation in a single gene, but different types of the 
same disease develop due to mutations in different 
genes. Selected cases were caused by mutations in gene 
for the adenosine deaminase (ADA).
19
 Patient 1 was 
Ashanti DeSilva. She was diagnosed with ADA 
deficiency when she was 26 months old. Treatment 
was polyethylene glycol-modified adenosine 
deaminase (PEG-ADA) as a replacement for the 
missing enzyme. Two years later, at the age of 4, the 
treatment resulted in the normal count of peripheral 
blood T cells which responded to mitogens in vitro. 
However, other signs of immunodeficiency were still 
present and Ashanti's T-cells lacked normal activity. 
Patient 2 was Cindy Kisik, at the age of 9. When she 
was three years old, she had first hazardous infection 
and at the age 5 she developed septic arthritis after 
which a milder form of SCID was diagnosed. She was, 
like Ashanti, given PEG-ADA treatment which at first 
led to increase of peripheral T-cells number, but their 
number again decreased in the third and fourth year of 
treatment. Both patients were supposed to receive gene 
therapy in parallel with application of PEG-ADA.
19
 
The procedure started with peripheral T-lymphocytes 
isolation from patients' blood that were afterwards, in 
cell culture, infected by retroviral vector which 





day, the cell population increased 135-fold and 
transformed T-cells were reinjected into patients' 
bodies. Ashanti received 11 transformed cell infusions 
in 2 years, and Cindy received 12 infusions in 
approximately 18 months. Ashanti had positive tests 
for T-cell activity 9 months after the beginning of the 
trial, and Cindy 17 months after the beginning of the 
trial. Patients' immune function improved and 
therapeutic doses of PEG-ADA were reduced. The 
treatment was completed in 1992. Four years later, 
normal T-cells count was still measured in both 
patients and the ADA gene expression in T cells 
continued. All other symptoms of the disease were also 
undetected.
19
 The patients' immune system grew 
stronger and it was more functional than it was during 
treatment with only PEG-ADA. After 23 years, the two 
cured patients participated at the Immune Deficiency 
Foundation National Conference as two healthy grown 
women.  
In the next few years after the SCID-ADA gene 
therapy success, development of gene therapy was in 
progress for various genetic diseases. However, in 
1999 at the age of 18 Jesse Gelsinger died after gene 
therapy treatment for ornithine transcarbamylase 
(OTC) deficiency.
20
 This metabolic disorder causes 
difficulty in removing ammonia from the body. 
Children born with it usually die 72 hours after birth. 
Jesse had a partial OTC deficiency, which was treated 
with available drugs and special protein reduced diet. 
Although gene therapy was not necessary, Institute for 
Human Gene Therapy at the University of 
Pennsylvania considered Jesse as a suitable candidate 
for clinical research that would help in the future 
treatment of other patients with the same disease. 
Based on patient's consent, recombinant adenoviruses 
with a functional OTC gene were injected into his 
hepatic artery. He had an almost immediate immune 
response to the vector and died four days after 
receiving the treatment. At that time, approximately 
400 gene therapy clinical trials were approved 




Afterwards, most research studies continued, but all 
preclinical studies had to include detailed and 




The development of commercially available drugs 
In 2003 Zhaohui Peng and his team from the company 
Shenthen developed an adenoviral vector Ad-p53 for 
treatment of head and neck squamous cell carcinoma. 
The study was approved by the State Food and Drug 
Administration (SFDA) of China and the drug 
appeared on Chinese market under the name 
Gendicine. It was the first commercially available 
adenovirus vector intended for gene therapy 
treatment.
21
 Gendicine is based on non-replicative and 
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non-pathogenic virus with inserted sequence for the 
human TP53 gene. This gene is the best-known tumor 
suppressor gene that controls cell division and DNA 
repair.  It codes for a transcription factor of 53 kDa that 
binds to various gene promoters, and through several 
steps, stimulates cell apoptosis. In 50% of cancer 
patients, p53 is mutated, while in a healthy individual 
this gene is in an inactive form and it is only activated 
when there is a triggered stress-response. Before 
Gendicine become available on the market, it was 
tested in phase I and phase II/III trials. In the first 
phase, 12 patients with advanced laryngeal carcinoma 
were treated. Drug was delivered by intratumoral 
injections, then tumor tissue was surgically removed, 
and drug was re-injecting in the prior tumor location. 
The only side effect was fever. All patients were 
successfully cured after 10 injections.
22
 The second and 
third phase consisted of 135 patients with squamous 
cell carcinoma of head and neck. Drug was injected 
directly to carcinoma tissue in combination with 
radiotherapy. It was shown that gene-therapy based 
drug in combination with radiotherapy provided faster 
and more efficient results than treatment with only 
radiotherapy.
23
 After Gendicine become commercially 
available in 2004, ethical considerations begun to arise 
because of the less rigorous procedure in processes for 
drug approval in China, in contrast to those in the 
USA.
22
 In 2005, Chinese SFDA approved another 
product: Oncorine (H101). Unlike the previous drug, 
this one was based on oncolytic therapy with a 
replicative adenovirus designed for treatment of late-
stage nasopharyngeal cancer. Oncolytic viruses are 
therapeutic viruses with ability to directly infect and 
destroy specifically cancer cells without damaging non-
tumor cells. Considering that mutations in the tumor 
suppressor gene p53 are some of the most common 
mutations present in malignant cells, this drug was 
designed as modified adenovirus which carries 
mutation in its E2B 55kD gene and causes this virus to 
preferentially destroy only those cells with mutated 




Another p53-based gene therapy treatment was 
designed for patients with Li-Fraumeni syndrome 
under the name Advexin. Advexin is based on 
adenoviral vector that carries functional p53 gene. 
When delivered to the cell that has abnormal p53 gene 
it is supposed to produce p53 tumor suppressor while 
not integrating itself into the host’s genome and 
enabling only transient expression of p53 gene. In this 
way, Advexin could serve as a replacement protein 
carrier that will help trigger protective mechanisms in a 
tumor cells and drive them to death. Gendux Molecular 
Limited applied to EMA for its approval in 2006. The 
company provided documents showing promising 
results in experimental models and based on one 
patient’s experience. In December 2008, Gendux 
withdrew its application based on, as stated in their 
letter to EMA, “the company’s marketing strategy”.
25
 
In September 2008 FDA issued Refuse to File Letter 
for the application of Advexin from Introgen 
Therapeutics, Inc., in this case intended for the 
treatment of head and neck cancer.
26
  
Few years later, in the western world the first drug for 
gene therapy was approved under the name Glybera. 
Glybera is an adeno-associated virus (AVV) vector 
which instead of virus pathogenic genes has an inserted 
lipoprotein lipase gene (LPL), intended for treating the 
lipoprotein lipase deficiency. This deficiency is a very 
rare hereditary disease which leads to an increase of fat 
in the blood. In clinical studies including 27 patients, it 
was shown that this drug leads to a reduction in blood 
fat concentration. Committee on Human Medicinal 
Products (CHMP) gave the final recommendation in 




On the European and USA markets, an increase in the 
number of approved gene therapy medicines has been 
recorded since 2016. In June 2016 European Medicines 
Agency (EMA) approved Strimvelis for the treatment 
of ADA deficiency. The treatment includes ex vivo 
modification of autologous hematopoietic stem cells 
with drug composed of a functional ADA gene packed 
into gamma retroviral vectors.
29
 Soon after, in August 
and October of 2017, the FDA approved two drugs for 
chimeric antigen receptor T cells (CAR-T) based 





 Their usage is based on in vitro 
modification of autologous T cells designed to express 
chimeric antigen receptor (CAR) to target and kill 
cancer B cells. The only difference between these two 
drugs is the type of vector which is used; lentiviral 
vector as a part of Kymriah drug and ϒ-retroviral 
vector as a part of Yescarta.
32
  
The last gene therapy drug in the western world was 
approved in December 2017 by FDA under the name 
Luxturna. It is intended for treatment of retinal 
dystrophy which occurs as a consequence of biallelic 
RPE65 mutation. The treatment is performed by 
subretinal injections of adeno-associated virus which 
carry a functional copy of human RPE65 gene to 
retinal cells.
33
   
Although gene therapy for various diseases became a 
reality, precise insertion of the introduced gene copy is 
still one of the challenges. Recent development of 
genome editing tools might improve this obstacle. 
 
 
Genome editing tools 
The idea of a precise, highly specific genetic editing 
tool that could introduce a targeted change in DNA 
sequence was encouraged by the fact that double 
stranded break (DSB) in the genomic DNA could be 
repaired through the process of non-homologous end 
joining (NHEJ) or homology-directed repair (HDR). 
Both pathways could be used in gene editing. NHEJ is 
the main and faster way of DSB repair because it is 
based on direct religation of cleaved ends of DNA 
molecule, but it can yield unpredictable mutations such 
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as deletions, insertions or substitutions. For these 
reasons it is mainly used in order to knock-out the 
activity of a target genomic region.
34
 HDR is a DSB 
repair based on the sister chromatid template, or 
another homologous sequence present in the cell, such 
as a DNA sequence introduced for therapeutic 
purposes. 
Based on these two naturally occurring mechanisms of 
DSB repair, genome editing tools were developed in 
order to specifically modify target genomic regions. 
Today, three gene editing tools with different levels of 
specificity and different approaches for eukaryotic cells 
are developed: zinc finger nucleases (ZFNs), 
transcription activator-like effector nucleases 
(TALENs), and clustered regularly interspaced short 
palindromic repeats/CRISPR-associated protein 9 
(CRISPR/Cas9). 
Zinc-finger nucleases (ZFNs) are the first tool designed 
for targeted genome engineering back in 1996. It 
consists of an artificial protein that contains one of the 
most common DNA binding protein domains in 
eukaryotes, the zinc-finger protein (ZFP) and FoxI 
endonuclease.
35
 ZFP is composed of tandem Cys2-His2 
binding domains which recognize 3-bp DNA 
segment.
36
 It is usually designed in a way that it 
contains 3 to 6 zinc finger-like protein domains in 
order to specifically bind to a unique genomic 
sequence.
37
 Two ZFN monomers are required for the 
recognition of the target sequence. Each of them 
recognizes the adjacent sequences in the antiparallel 
DNA chains separated by a spacer sequence of length 
between 5 and 7 bp. Spacer sequence provides a place 
for dimerization of FoxI which results in its activity 
and double-stranded DNA cleavage.
38
 ZFNs are the 
smallest type of genome editing tools, they contain 30 
amino acids to identify one base-pair triplet. 
Nowadays, commercial ZFNs kits can target on 
average every 50 bp in a random genome sequence.
39
 
This allows good coverage for gene knock-out by 
inducing small indels that might result in a frameshift 
mutation, but genome is not covered well enough for 
very precise site-specific modifications. 
In 2010 another class of sequence-specific nucleases 
was created by fusion of the transcription activator-like 
effectors (TALEs) and FoxI endonuclease.
40
 TALEs 
were originally identified as a product of plant 
pathogen bacteria in genus Xanthomonas. Their role is 
to bind sequences in genome of the infected plant cell 
and cause changes in plant gene expression with the 
aim of spreading bacterial infection.
41
 TALEs 
recognize specific DNA sequences with tandem repeats 
of DNA-binding domains composed of 33-35 amino 
acids. Amino acids at positions 12 and 13 of each 
domain, called repeat variable diresidues (RVDs), are 
recognizing one specific base pair.
37
 Such domains can 
be newly engineered, so specifically designed TALENs 
can recognize any sequence.
40
 As endonuclease FoxI is 
active only in a form of a dimer, it is necessary to 
design two TALEN complexes (similarly to ZFN 
complexes). Each one should position its FoxI 
endonuclease domain at an appropriate distance to the 
other one so that dimer can be formed and DSB 
produced.
42
 If the two pairs of opposite TALENs (or 
ZFNs) binding complexes are designed in a way that 
each pair makes one DSB, specific sequence can be 
removed from the genome by NHEJ repair mechanism. 
Another option is that, due to HDR, specific sequence 
can be replaced by the exogenous DNA through the 
process of homologous recombination.
42
 Compared to 
ZFNs, TALENs are simpler to use since there is a 
TALEN library which can target all human genes,
43
 
and they have lower cytotoxicity and lover off-target 
effect.
44
 General disadvantages of TALENs are their 
size - it requires 33-35 amino acids to identify one base 
pair, as well as their repetitive sequence which makes 




Beginning of discovery of the latest genome editing 
tool started in 1987. Yoshizumi Ishiniem's group 
conducted a research on E. coli and reported an unusual 
repetitive sequence downstream of the IAP gene. This 
sequence consisted of five highly homologous 29 
nucleotides long direct repeats separated by non-
repetitive 32 nucleotides, so called spacer sequences.
46
 
Similar repetitive DNA sequences were later found in 
many bacterial and archival species, but not in 
eukaryotes and viruses. Therefore, these sequences 
were recognized as parts of a gene family specific for 
prokaryotes.
47
 Because of their characteristic structure 
they were named the clustered regularly interspaced 
short palindromic repeats (CRISPR).
48
 Shortly 
afterwards, CRISPR-associated (Cas) protein-coding 
genes were identified adjacent to CRISPR loci in 
bacterial genomes,
48
 but function of the CRISPR 
family sequences was unknown until 2007 when 
Barrangou and colleagues showed that Streptococcus 
thermophilus can acquire immunity to phages by 
incorporating fragments of their genomic DNA into its 
own genome. Streptococcus pyogenes has four Cas 
genes (Cas9, Time1, Time2, and CSN2), genes coding 
crRNA (CRISPR targeting RNA) and tracrRNA (trans-
activating crRNA), as well as six different 30-nt long 
spacer sequences derived from viruses and plasmids, 
flanked at each side by a 36-nt long repeats.
49
 In other 
prokaryotes, spacer sequence length may vary from 21 
to 72 nt with the most common length between 32 to 
38 nt.
50
 During infection of the S. pyogenes adaptation 
happens - a viral or plasmid DNA fragment integrates 
into a bacterial CRISPR locus, which involves all four 
Cas genes products.
51
 Then, transcription of the locus 
leads to the assembly of an active DNA endonuclease 
complex consisting of three parts: (i) crRNA molecule 
partly complementary to the target DNA sequence, (ii) 
tracrRNA involved in the maturation of the crRNA, 
and (iii) Cas9 endonuclease which recognize 3-nt long 
protospacer adjacent motif (PAM sequence) juxtaposed 
to crRNA target DNA sequence. After the crRNA and 
Cas9 recognize the appropriate fragments of foreign 
DNA, Cas9 with its two nuclease domains; RuvC-like 
and  HNH-like   causes  a   DSB  in  foreign  DNA  and 
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 makes bacteria resistant to attackers.
52
  
The potential of bacterial immunity was soon 
recognized in the Doudna and Charpentier laboratory 
as a source for developing the third genome editing 
tool. According to the above-described mechanism, in 
2012 they developed CRISPR-Cas9 system with only 
two main components; Cas9 endonuclease and 
chimeric guide RNA (gRNA) which replaces crRNA 
and tracrRNA. By providing a synthetic gRNA, this 
system can recognize any sequence followed by PAM 
in eukaryotic genome and thus lead to its double-
stranded cleavage and modification.
53
 Unfortunately, it 
has been shown that in human cells, Cas9 can 
sometimes cleave DNA even when there is a mismatch 
between DNA and gRNA, or when there is a mismatch 
in PAM sequence. That is why along with target DSB, 
additional DSBs might be generated. When they are 
repaired by NHEJ mechanism, indel mutations emerge 
in different genomic sites. In order to choose optimal 
gRNA and to predict nonspecific binding, in silico 
tools were designed.
54
 Despite that, the off-target 
activity still exists. Therefore, to avoid it, two 
alternative variants of original CRISPR-Cas9 system 
were developed; (i) Cas9 nickase and (ii) Cas9-FokI 
nuclease. In both cases, position of DSB is determined 
by the pair of monomeric variants where each gRNA 
recognizes a particular adjacent sequence around 
targeted site, effectively making the target recognition 
sequence doubled. Cas9 nickase is a modified variant 
of Cas9 nuclease that cleaves only one strand in 
dsDNA. Adjacent sequences in antiparallel chains are 
recognized and nicked by a pair of colocalized Cas9 
nickase - gRNA complexes, then two formed nicks 
result with a DSB. The main advantage of paired 
nicking strategy is reduced off-target mutations 
because non-specific nicks are repaired with much 
higher fidelity than DSBs.
55
 Unlike Cas9 nickase, 
Cas9-FokI nuclease needs dimerization for its activity. 
Two different gRNAs lead Cas9-FokI monomers at the 
target location and appropriate distance at which FokI 
nuclease dimerizes and forms DSB. This Cas9 variant 
proved to be an improvement since it induced lower 
frequency of indel mutations.
56
 Targeting of the 
CRISPR-Cas9 complex to any sequence in the genome 
of a cell only requires a simple design and synthesis of 
a new guide RNA, as opposed to the labor-intensive re-
design of protein-based ZFNs and TALENs. It has 
already been mentioned that all of these genome 
editing tools cause off-target effects. Despite off-target 
effects, CRISPR-Cas9 system proved to be the most 
effective and the best choice for multiple editing of 





Clinical use of new tools 
Described genome editing tools can be used in in vivo 
and ex vivo gene therapy and there are several ways to 
introduce them into the target cells. In ex vivo gene 
editing, cells are modified outside of the patient's body 
and then reinfused back. Usually, DNA or mRNA 
coding for ZFN, TALEN, CRISPR/Cas9 with gRNA 
can be delivered to target cells by electroporation, 
lentiviral vectors or simply by direct introduction of 
protein complexes.
58
 In contrast to ex vivo, the in vivo 
gene editing methods are more complex as they include 
process of bringing these tools to a specific type of 
cells in the specific tissue of the body. The most 
studied vectors so far for in vivo gene therapy are 
adeno-associated virus vectors (AAV). These are 
viruses that instead of their own pathogenic genes carry 
a coding sequence for genome editing tools and 
therapeutic genes. The capacity of AAV is 
approximately 4.8 kb of DNA, whereas the synthesis of 
only one TALEN monomer requires cDNA larger than 
4 kb, and the synthesis of Cas9 originating from S. 
pyogenes requires 4.2 kb cDNA, while ZFN requires 
only about 1 kb. Therefore, the new goal is to develop 
a method in which just one vector would code the 
entire product needed for a successful gene therapy.
58
 
Additionally, all genome editing tools, ZFNs, TALENs 
and CRISPR/Cas9 systems show certain level of off-
target action. Therefore, the screening of unwanted 
mutations and further optimization of these tools 
should improve gene editing specificity. 
ZFN was the first of described tools that was used in 
the clinical trial. The study was conducted between 
May 2009 and July 2012 with the goal of curing AIDS 
by creating an immune system resistant to HIV 
infection. T-cells co-receptor CCR5 is often the one 
responsible for the entry of HIV into the cell. 
Homozygotes with a 32-bp deletion in the CCR5 gene 
are resistant to HIV infection and in heterozygotes 
progression of the disease is slower. According to these 
data, in the clinical study conducted on 12 patients, 
CD4 T cells were cultured and exposed to a pair of 
CCR5-specific ZFNs. DSB formed within the CCR5 
gene region were repaired by NHEJ repair which led to 
aberrant truncated gene and non-functional protein 
presented on the cell surface. Study followed the safety 
and tolerability criteria for a single dose modified 




Furthermore, ZFNs are the first genome editing tool 
that has been used in in vivo human genome editing 
trials. At the 56 Annual Symposium of the Society for 
the Study of Inborn Errors of Metabolism (SSIEM) 
held in September 2018, the update from a Phase 1/2 
clinical trial intended for curing the 
mucopolysaccharidosis II (MPSII or Hunter Syndrome) 
was presented. MPSII occurs as a consequence of 
mutation in the gene for the enzyme iduronate-2-
sulphate (IDS) responsible for breakdown of some 
complex sugars. SB-913 drug which targets the liver 
cells was constructed. It is composed of two ZFNs-
nucleases and one functional donor IDS gene packaged 
in AAV. Sixteen weeks after the treatment onset, in 
two out of four patients who received a higher dose of 
medication, reduction in the amount of urinary 
glycosaminoglycan associated with this disease was 
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reported. Although expected, there was no increase in 
the amount of IDS enzyme in plasma. Currently, two 
more clinical trials are being carried out by in vivo 
ZFN-mediated gene therapy: treatment for 
mucopolysaccharidosis I (MPSI) and hemophilia B.
60-63
  
TALEN was applied in clinical treatment for the first 
time in June 2015. An 11-month-old infant girl in the 
late stage of acute lymphoblastic leukemia with a 
barely functioning immune system and with 
insufficient T-lymphocytes for personalized therapy, 
intravenously received TALEN-modified T cells of a 
healthy donor named UCART19 cells. Donor T-cells 
were modified with inactivation of two genes: (i) T cell 
receptor gene (so that patient's immune system cannot 
develop response to foreign cells), and (ii) CD52 gene - 
targeted molecule for therapy with Campath that the 
patient was receiving. Campath contains of 
mononuclear antibodies which bind a CD52 antigen on 
T cells, which allow the immune system to recognize 
and destroy labelled cancer cells. This way, functional 
donor T-cells became invisible to the therapy. Three 
months later patient received bone marrow 
transplantation and significant recovery was noted. In a 
report made 18 months after therapy, the patient 
showed no signs of illness.
64, 65
 In December 2015 a 
similar form of treatment was applied to another 16-
month-old infant girl with a diagnosis of acute 
lymphoblastic leukemia. Twelve months later, the 
patient showed no signs of disease
65
 
The first official clinical trial using CRISPR-Cas9 
technology, will be the one led by a partnership 
between USA company Vertex Pharmaceuticals and 
European company CRISPR Therapeutics. They 
developed the CTX001 ex vivo autologous therapy 
intended for treating one of the most common 
monogenic diseases, β-thalassemia. It has been shown 
that the presence of fetal hemoglobin in patients with 
β-thalassemia can replace the function of adult one.
66
 
Therefore, this therapy is not focused on replacing the 
mutated form of HBB gene with a functional one, but it 
is directed to encourage re-production of fetal 
hemoglobin. CTX001 therapy with CRISPR-Cas9 
technology will stimulate re-production of fetal 
hemoglobin by mutating the coding sequence of 
BCL11A transcription factor, a negative regulator of 
fetal hemoglobin expression. Hematopoietic progenitor 
cells will be harvested and modified ex vivo by this 
technology and then reinfused to the patient's body. It 
is expected that FDA will soon give final approval for 
the start of Phase1/2 of this clinical trial.
67, 68
 
New studies in the field of developing innovative 
techniques and therapies for other disorders using gene 
editing will surely continue. Besides that, these tools 
have also a promising potential in precise epigenetic 
manipulations. By removing their nuclease activity and 
fusing them with proteins such as transcription factors 
and enzymes for epigenetic remodeling, they can be 
directed to any genomic site to change its epigenetic 
status. We presume that new tools like CRISPR-Cas9 





 and targeted histone modification
71
 as 





 will soon emerge 
and more preclinical trials will follow. 
Despite many benefits these tools bring to the 





Taken together, some of the main obstacles to a 
successful gene therapy are: bringing therapeutic genes 
into targeted cells without disturbing regulatory and 
transcriptionally active regions in the cell genome; 
development of adequately large and non-
immunogenic vectors; and high cost of treatment. 
Nevertheless, gene therapy is a revolutionary method 
directed to the treatment of genetic diseases at the very 
cause of the disease itself. It allows the treatment of 
various inherited diseases as well as diseases acquired 
during life. New developments in the field of genome 
editing tools may soon be a starting point for cure of all 
diseases caused by a change in gene function, not only 
on genetic but as well as on epigenetic level. This 
technological advancement must be accompanied by 
solving issues that genome editing brings: delivery of 
treatment in the aimed cells, quality of preclinical 
research, ethical standards and most of all - 
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